Selecting patients with severe sepsis for drotrecogin alfa (activated) therapy

American Journal of Surgery

Volumn 184, Issue 6 SUPPL. 1, 2002, Pages S11-S18

  Sollet, Jean Pierre ^a   Garber, Gary E ^b  

^a CENTRE HOSPITALIER VICTOR DUPOUY   (France)

^b UNIVERSITY OF OTTAWA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DROTRECOGIN;

ARTICLE; CLINICAL TRIAL; DEATH; DIAGNOSTIC ACCURACY; DISEASE SEVERITY; HUMAN; INFECTION; MULTIPLE ORGAN FAILURE; PATIENT SELECTION; PRIORITY JOURNAL; SEPSIS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

EID: 0036939629     PISSN: 00029610     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9610(02)01132-7     Document Type: Article

References (29)

1. Zeni F., Freeman B., Natanson C. Anti-inflammatory therapies to treat sepsis and septic shock a reassessment . Crit Care Med. 25:1997;1095-1100.
2. Opal S.M. Clinical trial design and monitoring in severe sepsis interventions. Balk R.A. Advances in the Diagnosis and Management of the Patient with Severe Sepsis. 2002;59-72 Royal Society of Medicine Press, London.
3. Bernard G.R., Vincent J.L., Laterre P.F., et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med. 344:2001;699-709.
4. Bone R.C., Balk R.A., Cerra F.B., et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest. 101:1992;1644-1655.
5. Levy M. The challenge of sepsis: epidemiology and definitions. Paper presented at: Society of Critical Care Medicine Annual Meeting; January 30, 2002; San Diego, CA.
6. Simon D., Trenholme G. Antibiotic selection for patients with septic shock. Crit Care Clin. 16:2000;215-231.
7. Bernard G.R. Research in sepsis and acute respiratory distress syndrome are we changing course? Crit Care Med. 27:1999;434-436.
8. Vincent J.L. Dear SIRS, I'm sorry to say that I don't like you. Crit Care Med. 25:1997;372-374.
9. Brun-Buisson C., Doyon F., Carlet J., et al. Incidence, risk factors, and outcome of severe sepsis and septic shock in adults. A multicenter prospective study in intensive care units. French ICU Group for Severe Sepsis. JAMA. 274:1995;968-974.
10. Bernard G.R., Wheeler A.P., Russell J.A., et al. The effects of ibuprofen on the physiology and survival of patients with sepsis. The Ibuprofen in Sepsis Study Group. N Engl J Med. 336:1997;912-918.
11. Warren B.L., Eid A., Singer P., et al. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis a randomized controlled trial . JAMA. 286:2001;1869-1872.
12. Cohen J., Carlet J. INTERSEPT an international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis. International Sepsis Trial Study Group . Crit Care Med. 24:1996;1431-1440.
13. Reinhart K., Wiegand-Lohnert C., Grimminger F., et al. Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock a multicenter, randomized, placebo-controlled, dose-ranging study . Crit Care Med. 24:1996;733-742.
14. Biologics License Application: Recombinant Human Activated Protein C (rhAPC) [Drotrecogin Alfa (Activated)] Xigris for Severe Sepsis. US Food and Drug Administration Web site. Available at: http://www.fda.gov/ohrms/dockets/ac/01/slides/3797s1_02_Forsyth/sld023.htm. Accessed.
15. Angus D.C., Linde-Zwirble W.T., Lidicker J., et al. Epidemiology of severe sepsis in the United States analysis of incidence, outcome, and associated costs of care . Crit Care Med. 29:2001;1303-1310.
16. Sprung C.L., Finch R.G., Thijs L.G., Glauser M.P. International sepsis trial (INTERSEPT) role and impact of a clinical evaluation committee . Crit Care Med. 24:1996;1441-1447.
17. Kollef M.H., Sherman G., Ward S., Fraser V.J. Inadequate antimicrobial treatment of infections a risk factor for hospital mortality among critically ill patients . Chest. 115:1999;462-474.
18. US Food and Drug Administration. Drotrecogin alfa (activated) (recombinant human activated protein C [rhAPC]), Xigris, BLA #125029/0. FDA Briefing Information. September 12, 2001. Available at: http://www.fda.gov/ohrms/dockets/ac/01/briefing/3787b1.htm. Accessed August 1, 2002.
19. Rangel-Frausto M.S., Pittet D., Costigan M., et al. The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study. JAMA. 273:1995;117-123.
20. Sands K.E., Bates D.W., Lanken P.N., et al. Epidemiology of sepsis syndrome in 8 academic medical centers. Academic Medical Center Consortium Sepsis Project Working Group. JAMA. 278:1997;234-240.
21. Dhainaut J.F., Tenaillon A., Le Tulzo Y., et al. Platelet-activating factor receptor antagonist BN 52021 in the treatment of severe sepsis a randomized, double-blind, placebo-controlled, multicenter clinical trial. BN 52021 Sepsis Study Group . Crit Care Med. 22:1994;1720-1728.
22. Opal S.M., Fisher C.J. Jr, Dhainaut J.F., et al. Confirmatory interleukin-1 receptor antagonist trial in severe sepsis a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group . Crit Care Med. 25:1997;1115-1124.
23. Fein A.M., Bernard G.R., Criner G.J., et al. Treatment of severe systemic inflammatory response syndrome and sepsis with a novel bradykinin antagonist, deltibant (CP-0127). Results of a randomized, double-blind, placebo-controlled trial. CP-0127 SIRS and Sepsis Study Group. JAMA. 277:1997;482-487.
24. Bollaert P.E., Charpentier C., Levy B., et al. Reversal of late septic shock with supraphysiologic doses of hydrocortisone. Crit Care Med. 26:1998;645-650.
25. Inthorn D., Hoffmann J.N., Hartl W.H., et al. Antithrombin III supplementation in severe sepsis beneficial effects on organ dysfunction . Shock. 8:1997;328-334.
26. Michard F., Boussat S., Chemla D., et al. Relation between respiratory changes in arterial pulse pressure and fluid responsiveness in septic patients with acute circulatory failure. Am J Respir Crit Care Med. 162:2000;134-138.
27. Balk R.A. Pathogenesis and management of multiple organ dysfunction or failure in severe sepsis and septic shock. Crit Care Clin. 16:2000;337-352.
28. Abraham E., Anzueto A., Gutierrez G., et al. Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. NORASEPT II Study Group. Lancet. 351:1998;929-933.
29. Draper E.A., Wagner D.P., Knaus W.A. The use of intensive care a comparison of a university and community hospital . Health Care Financing Review. 3:1981;49-64.